Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name LY3295668
Synonyms
Therapy Description

LY3295668 selectively inhibits Aurora A kinase (AURA), which results in apoptosis, inhibition of cell proliferation, and tumor growth inhibition (PMID: 31530649).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
LY3295668 LY3295668 erbumine|AK-01 Aurka Inhibitors 26 LY3295668 selectively inhibits Aurora A kinase (AURA), which results in apoptosis, inhibition of cell proliferation, and tumor growth inhibition (PMID: 31530649).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
RB1 loss Merkel cell carcinoma sensitive LY3295668 Preclinical - Pdx & cell culture Actionable In a preclinical study, LY3295668 resulted in cell growth inhibition and increased cell cycle arrest and apoptosis in Merkel cell carcinoma patient-derived cell lines with loss of Rb1 expression in culture, and resulted in reduced tumor growth in a patient-derived xenograft (PDX) model (PMID: 34359608). 34359608

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04106219 Phase I LY3295668 Cyclophosphamide + LY3295668 + Topotecan A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | BEL | AUS 1
NCT03955939 Phase I LY3295668 + Midazolam LY3295668 A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body Completed USA | BEL 0
NCT03092934 Phase Ib/II LY3295668 A Study of AK-01 (LY3295668) in Solid Tumors Completed CAN 0
NCT03898791 Phase Ib/II LY3295668 A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer Completed USA | GBR | FRA | ESP | BEL 3


Additional content available in CKB BOOST